Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure

Susan Howard; Susan J. Howard; Dasa Cerar; Michael J. Anderson; Ahmed Albarrag; Matthew C. Fisher; Alessandro C. Pasqualotto; Michel Laverdiere; Maiken C. Arendrup; David S. Perlin; David W. Denning

doi:10.3201/eid1507.090043

Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure

Susan Howard, Susan J. Howard, Dasa Cerar, Michael J. Anderson, Ahmed Albarrag, Matthew C. Fisher, Alessandro C. Pasqualotto, Michel Laverdiere, Maiken C. Arendrup, David S. Perlin, David W. Denning

Research output: Contribution to journal › Article › peer-review

Abstract

Azoles are the mainstay of oral therapy for aspergillosis. Azole resistance in Aspergillus has been reported infrequently. The first resistant isolate in Manchester, UK, was detected in 1999. In a clinical collection of 519 A. fumigatus isolates, the frequency of itraconazole resistance was 5%, a significant increase since 2004 (p

Original language	English
Pages (from-to)	1068-1076
Number of pages	8
Journal	Emerging infectious diseases
Volume	15
Issue number	7
DOIs	https://doi.org/10.3201/eid1507.090043
Publication status	Published - Jul 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3201/eid1507.090043

http://www.cdc.gov/eid/content/15/7/pdfs/1068.pdf

Defining global antifungal azole resistance in Aspergillus – enhancing diagnostics and driving drug discovery
David Denning (Participant), Peter Warn (Participant), Michael Bromley (Participant), Paul Bowyer (Participant) & Caroline Moore (Participant)
Impact: Health and wellbeing, Policy, Economic
Diagnostics and novel life-saving therapies for aspergillosis
David Denning (Participant), Michael J. Anderson (Participant), Caroline Moore (Participant), Peter Warn (Participant), Paul Bowyer (Participant), Michael Bromley (Participant), Nicola Smith (Participant), Susan Howard (Participant) & Robert Niven (Participant)
Impact: Health impacts

Cite this

@article{581bca8f65074990a37dc6a0159a4d7c,

title = "Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure",

abstract = "Azoles are the mainstay of oral therapy for aspergillosis. Azole resistance in Aspergillus has been reported infrequently. The first resistant isolate in Manchester, UK, was detected in 1999. In a clinical collection of 519 A. fumigatus isolates, the frequency of itraconazole resistance was 5%, a significant increase since 2004 (p",

author = "Susan Howard and Howard, {Susan J.} and Dasa Cerar and Anderson, {Michael J.} and Ahmed Albarrag and Fisher, {Matthew C.} and Pasqualotto, {Alessandro C.} and Michel Laverdiere and Arendrup, {Maiken C.} and Perlin, {David S.} and Denning, {David W.}",

year = "2009",

month = jul,

doi = "10.3201/eid1507.090043",

language = "English",

volume = "15",

pages = "1068--1076",

journal = "Emerging infectious diseases",

issn = "1080-6040",

publisher = "U.S. Department of Health and Human Services Centers for Disease Control and Prevention",

number = "7",

}

TY - JOUR

T1 - Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure

AU - Howard, Susan

AU - Howard, Susan J.

AU - Cerar, Dasa

AU - Anderson, Michael J.

AU - Albarrag, Ahmed

AU - Fisher, Matthew C.

AU - Pasqualotto, Alessandro C.

AU - Laverdiere, Michel

AU - Arendrup, Maiken C.

AU - Perlin, David S.

AU - Denning, David W.

PY - 2009/7

Y1 - 2009/7

N2 - Azoles are the mainstay of oral therapy for aspergillosis. Azole resistance in Aspergillus has been reported infrequently. The first resistant isolate in Manchester, UK, was detected in 1999. In a clinical collection of 519 A. fumigatus isolates, the frequency of itraconazole resistance was 5%, a significant increase since 2004 (p

AB - Azoles are the mainstay of oral therapy for aspergillosis. Azole resistance in Aspergillus has been reported infrequently. The first resistant isolate in Manchester, UK, was detected in 1999. In a clinical collection of 519 A. fumigatus isolates, the frequency of itraconazole resistance was 5%, a significant increase since 2004 (p

U2 - 10.3201/eid1507.090043

DO - 10.3201/eid1507.090043

M3 - Article

C2 - 19624922

VL - 15

SP - 1068

EP - 1076

JO - Emerging infectious diseases

JF - Emerging infectious diseases

SN - 1080-6040

IS - 7

ER -

Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure

Abstract

UN SDGs

Access to Document

Fingerprint

Impacts

Defining global antifungal azole resistance in Aspergillus – enhancing diagnostics and driving drug discovery

Diagnostics and novel life-saving therapies for aspergillosis

Cite this